4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by research analysts at Weiss Ratings in a research report issued on Thursday,Weiss Ratings reports.

Other research analysts have also issued reports about the stock. Morgan Stanley decreased their price objective on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating for the company in a report on Monday, January 13th. Chardan Capital lowered their price target on 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Leerink Partners lowered their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating on the stock in a research report on Monday, January 13th. Bank of America lowered their price objective on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Finally, Royal Bank of Canada dropped their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $26.71.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock traded up $0.13 on Thursday, reaching $3.37. 302,018 shares of the company traded hands, compared to its average volume of 831,327. The firm has a market capitalization of $156.04 million, a PE ratio of -1.18 and a beta of 2.89. The company has a 50 day moving average of $3.54 and a 200 day moving average of $5.55. 4D Molecular Therapeutics has a 52 week low of $2.24 and a 52 week high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). As a group, analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several large investors have recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at approximately $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at $50,000. PNC Financial Services Group Inc. lifted its stake in 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock valued at $51,000 after buying an additional 3,630 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of 4D Molecular Therapeutics by 5,291.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock worth $55,000 after buying an additional 9,737 shares during the last quarter. Finally, Velan Capital Investment Management LP acquired a new position in 4D Molecular Therapeutics in the 4th quarter valued at $56,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.